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Ligands that specifically target retinoid-X receptors
(RXRs) are emerging as potentially powerful therapies
for cancer, diabetes, and the lowering of circulatory
cholesterol. To date, RXR has only been crystallized in
the absence of ligand or with the promiscuous ligand
9-cis retinoic acid, which also activates retinoic acid
receptors. Here we present the structure of hRXR in
complex with the RXR-specific agonist LG100268
(LG268). The structure clearly reveals why LG268 is spe-
cific for the RXR ligand binding pocket and will not
activate retinoic acid receptors. Intriguingly, in the
crystals, the C-terminal “activation” helix (AF-2/helix
H12) is trapped in a novel position not seen in other
nuclear receptor structures such that it does not cap the
ligand binding cavity. Mammalian two-hybrid assays in-
dicate that LG268 is unable to release co-repressors
from RXR unless co-activators are also present. To-
gether these findings suggest that RXR ligands may be
inefficient at repositioning helix H12.
The retinoid-X receptors (RXR, , and )1 are nuclear re-
ceptors that regulate differentiation, development, and home-
ostasis in response to ligand (1–5). RXRs can act as either
homodimers or heterodimers with other nuclear receptors (1,
6–8). The ability to serve as the preferred heterodimeric part-
ner of many (10) other receptors makes RXRs unique within
the family of nuclear receptors and accounts for their role in
many diverse signaling pathways. It is generally held that 9-cis
retinoic acid (9cRA) is the natural ligand for RXRs (9, 10). This
is a promiscuous ligand because it also activates retinoic acid
receptors (RARs), which themselves serve as heterodimeric
partners for RXR. Chemical approaches have led to the devel-
opment of synthetic agonists that allow RXR to be activated
without influencing the activity of RARs (11, 12). It has
emerged that RXR-specific agonists such as Targretin and
LG268 may serve as beneficial therapies for the treatment of
cancer, diabetes, and other metabolic disorders (13–15). LG268
is a substituted stilbene (6-[1-(3,5,5,8–8-pentamethyl-5,6,7,8-
tetrahydronapthalen-2-yl)-cycloproyl]-nicotinic acid) that spe-
cifically binds to and activates RXRs, but not RARs, with a
slightly higher affinity than 9cRA (9–11).
Structural and biochemical studies of a number of nuclear
receptor ligand-binding domains (LBDs) have yielded a rela-
tively simple model for the mechanism by which ligands regu-
late nuclear receptor activity. The LBDs of nuclear receptors
share a common, predominantly helical fold (16, 17). In the
absence of ligand, co-repressor proteins bind to the surface of
the LBD and prevent the C-terminal helix H12 (AF2-helix)
from binding to the surface of the receptor (18–20). Activating
ligands bind in a hydrophobic cavity within the core of the LBD
and cause the repositioning of helix H12 such that it seals the
ligand binding cavity, resulting in the displacement of co-re-
pressor. In this position, helix H12 forms a critical part of the
binding site for co-activator proteins (21, 22). Significantly,
ligands that do not activate nuclear receptors (competitive
antagonists) appear to exert their effect by displacing helix H12
from its “active position” so that it occupies the co-activator
binding site, the so-called antagonist conformation, and thus
prevents co-activator binding (23, 24). Furthermore ligands
that act as partial agonists have been found to cause helix H12
to adopt a similar position to that seen with full antagonists
(25).
Here we present the first structure of RXR bound to a selec-
tive agonist, LG268. This structure shows clearly why LG268
will bind only to RXR and not to RARs. It also suggests why
LG268 has a somewhat higher affinity for RXR than does 9cRA
and why it is a more potent agonist. The liganded RXR forms a
stable homodimer with the interface very similar to that of the
apo-homodimer (26, 27). Finally, helix H12 adopts a novel
position not seen in other liganded nuclear receptors. Although
this position may be favored in the crystal lattice, it suggests
that helix H12 is only weakly recruited to the canonical active
position on binding ligands. Support for this comes from mam-
malian two-hybrid experiments showing that, unlike with
other receptors, both ligand and co-activator are required to
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displace co-repressor and hence suggesting that co-activator
helps to stabilize the helix in the active conformation.
EXPERIMENTAL PROCEDURES
Expression, Purification, and Crystallization—The ligand-binding
domain of hRXR (amino acids 296–533) was over-expressed in Esch-
erichia coli (BL21(DE3)) and purified as a stoichiometric heterodimer
with hRAR as described previously (28). The pure protein, in a buffer
containing 10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1.0 mM dithiothreitol,
and 0.125% (v/v) Triton X-100, was incubated for 16 h with LG268 and
TTNPB at a 1.2 molar excess and subsequently concentrated to 7.4
mg/ml using a Centricon concentrator (Amicon). Ligands dissolved in
Me2SO were diluted in the protein solution such that the final Me2SO
concentration was 1%.
Crystals were grown at 20 °C using the vapor diffusion method. 2-l
drops were equilibrated against 1.4 M ammonium formate, pH 7.6.
Irregular plate crystals (400  300  20 m) formed after 3 months
in a bed of precipitate that was found to be denatured hRAR LBD.
Small crystals of the hRXR LBD (expressed without the hRAR LBD)
could be grown under similar conditions but without detergent, sug-
gesting that the detergent plays a role in dissociating the heterodimer
but not in the crystallization itself. Crystals were harvested using a
400-m loop mounted on a pin and frozen by being plunged into liquid
nitrogen using the reservoir solution supplemented with 25% glycerol
as a cryoprotectant. Analysis of the crystals suggested that the hRXR
LBD had not been proteolyzed during crystallization.
Structure Solution and Refinement—X-ray diffraction data were col-
lected at 100 K using a refrigerated nitrogen gas delivery system at
beamline ID14–2 ESRF (Grenoble, France) on an area detector systems
Quantum-4 CCD. Data were processed using Mosflm (29) and further
using the CCP4 package (30). The best crystals diffracted beyond 2.5 Å
with useful data to 2.7 Å. Data processing statistics are shown in Table
I. The structure was solved by molecular replacement with a search
model comprising a dimer, the apo-RXR LBD (amino acids 225–431)
lacking the C-terminal structural elements helices H11 and H12. Clear
rotation and translation function solutions were obtained using CNS
(15–4 Å) (31). The initial R-factor following rigid body refinement was
46.9%. The sigma-a weighted 2Fo  Fc map was substantially improved
using NCS averaging and solvent flipping implemented in CNS. Strict
NCS restraints were imposed followed by four rounds of rebuilding and
refinement in O (32) and CNS, respectively. The NCS restraints were
then released, and further refinement gave a final model for which
statistics are shown in Table I.
Transient Transfection Experiments—Mammalian expression vec-
tors used in this work have been described previously (18) with the
exception of the ACTR vector, which was based on the pcDNA3.1
vector (Invitrogen) and contained the receptor interaction domain
(amino acids 621–821) with an N-terminal nuclear localization signal
from SV40. CV1 cells were transiently transfected as described pre-
viously (18). Luciferase activity for each sample was normalized with
reference to the level of -galactosidase activity of a control reporter
construct. Each transfection was carried out in triplicate at least
three times.
RESULTS
Structure Determination—hRXR:LG268 crystallized in
space group C2 with two LBD dimers in the asymmetric unit.
The structure was solved by molecular replacement using a
truncated version of the apo-hRXR dimer as the search model
(33). The structure of the apo-hRXR was chosen as a starting
model because it is the only available RXR homodimer struc-
ture and it would serve as an unbiased model from which to
interpret the structural changes on binding ligand. An excel-
lent electron density map was obtained by averaging according
to the 4-fold noncrystallographic symmetry. The map showed
clear electron density for the majority of the hRXR LBD and
the bound ligand, LG268. However the extreme N and C ter-
mini of the LBD could not be assigned in the electron density
map nor could an internal loop between helices H1 and H3
(amino acids 312–334).
Crystal Packing—The hRXR LBDs are packed in the crys-
tal lattice as octamers (two asymmetric units) with each mon-
omer making extensive contacts to two other LBDs (Fig. 1a).
One of these two interfaces is clearly the biologically relevant
homodimerization interface (marked HDI) with a buried sur-
face of 2250 Å2. The other interface, which buries 1660 Å2,
arises as part of the crystal packing (marked CPI). Additional
electron density seen at this second interface could not be
attributed to protein and is most likely either a partially or-
dered detergent molecule or an additional molecule of the li-
gand. Because of this ambiguity, no model was fitted to this
density or included in the refinement.
Adjacent octamers pack together in the crystal lattice with a
tightly bound metal ion at the interface (shown as gray spheres,
Fig. 1a). This ion, chelated by His-402 and His-404 in one
monomer and by Asp-390 in another, was assigned as a Ni2
ion that was presumably retained during the purification on
the nickel-nitrilotriacetic acid resin. There is clearly additional
density for a fourth ligand for the Ni2, which was tentatively
modeled as a chloride ion.
Overall Structure—The hRXR:LG268 structure has an
overall architecture similar to that of LBDs from other mem-
bers of the nuclear receptor family (16). To facilitate compari-
son with other structures, we used a secondary structure num-
bering scheme based on the original apo-hRXR structure (33).
The hRXR LBD consists of a three-layer helical sandwich
(Fig. 1b). Helices H1 and H3 comprise one outer layer (joined by
a disordered loop). The central layer comprising helices H4, H5,
H8, and H9 is incomplete, leaving a cavity that accommodates
bound ligand. The final layer comprises helices H7, H9, and
H10/H11 and forms the homodimer interface between the two
LBD monomers. The position of helix H12 in the hRXR:LG268
complex differs from that seen in previous RXR structures (Fig.
1, c–e). The significance of this difference is discussed further
below.
Ligand Binding—The initial electron density map, averaged
according to the noncrystallographic symmetry, showed unam-
biguous density for the LG268 ligand (Fig. 2a). It is enclosed in
a largely hydrophobic cavity (568 Å3) bounded by helices H3,
H5, H7, and H11 and a -sheet. The ligand (355 Å3) occupies
63% of the cavity, making extensive contacts with the protein
(Fig. 2b). The majority of contacts are nonpolar van der Waals
interactions. However, the carboxylate of the nicotinic acid
group forms a salt bridge with Arg-387 and accepts hydrogen
bonds from the backbone amide of Ala-342 and an ordered
water molecule. Ile-339, Leu-380, and Phe-384 contact the pi-
peridine ring, and the cyclopropyl group is in close contact with
Trp-376, Asn-377, and Ile-381. Significantly there is no hydro-
gen bonding partner for the nitrogen in the piperidine ring, and
therefore the rotational orientation of the ring could not be
assigned.
The naphthalene ring, with its five methyl substituents,
makes the bulk of the van der Waals interactions with the
protein and contacts 10 side chains within the ligand binding
TABLE I
Data collection, processing, and refinement statistics
Rmerge  I  	I
/	I
; Rcryst and Rfree  Fobs  Fcalc/Fobs. RMSD,
root-mean-square deviations from ideal values.
X-ray source/wavelength ESRF ID14–2/0.933Å
Resolution (outer shell) 38–2.7 (2.87–2.7) Å
Total/unique reflections 87647/29713
Redundancy/completeness 2.9/97.8%
Rmerge (outer shell) 9.8% (26.4%)
I/ (outer shell) 5.1 (2.1)
Space group C2, a  123.89, b  106.88,
c  100.59,   122.56
Rcryst/Rfree (10%) 27.7/30.1%
RMSD bonds/angles 0.009Å/1.4°
Average B-factor 51.0 Å3
Ramachandran
Favored/additional/generous 91.8/8.2/0.0%
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FIG. 1. Comparison of hRXR:LG268 with hRXR structures. a, hRXR:LG268 packs within the crystal as a tetramer of homodimers. HDI
and CPI indicate the homodimer and crystal packing interfaces, respectively. The gray spheres indicate nickel ions that are involved in
interoctamer packing interactions. b, structure of hRXR:LG268. The helices that make up the three-layer antiparallel -helical sandwich are
shown in green. Helix H12 is shown in yellow, adopting a position reminiscent of the apo-hRXR ligand-binding domain. c–e, structures of hRXR
showing the various orientations adopted by helix H12 (yellow). hRXR:9cRA (38) (Protein Data Bank code 1fby), mRXR*-oleic acid (36) (Protein
Data Bank code 1dkf), and apo-hRXR (33) (Protein Data Bank code 1lbd).
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cavity. The methyl on the unsaturated ring of the naphthalene
makes van der Waals contacts to Cys-340, Ala-343, and Leu-
507 and protrudes out from the ligand binding cavity toward
the canonical position of helix H12. Comparison with other
liganded RXR structures suggests that the methyl would be in
close van der Waals contact with Leu-522 in helix H12 if it were
in the canonical agonist position.
Comparison with hRXR Bound to 9cRA—LG268 binds to all
three RXR isoforms with a dissociation constant of 3 nM (11);
this contrasts with the somewhat weaker dissociation constant
of 9cRA (9–12 nM for hRXR) (9, 10). Notably, LG268 also gives
50% maximal activation at a concentration at least 10-fold
lower than 9cRA (34).
The general pattern of the contacts between RXR and
LG268 is very similar to that seen in the RXR:9cRA structure.
The similarity extends to the presence of an ordered water
molecule in the ligand cavity and is unsurprising because both
ligands are in van der Waals contacts with all of the side chains
exposed in the interior of the ligand binding cavity (Fig. 2b).
The only differences involve side chain rearrangements to ac-
commodate the different shape of LG268. The most significant
rearrangements are those of residues Cys-503, Phe-510, and
Arg-387 (Fig. 2c). Notably, the orientation of Cys-503 seen in
the hRXR:9cRA structure is incompatible with LG268 bind-
ing, as it would result in a severe steric clash. Rotation about
the C–C bond allows the Cys-503 to accommodate LG268
binding, but in this new position it would clash with 9cRA. The
movement of Cys-503 also requires the further rearrangement
of the side chain of Ile-416.
Structural Basis for the Specificity of LG268—In contrast to
the promiscuous properties of 9cRA, which also activates reti-
noic acid receptors (RARs), LG268 is highly specific for RXRs
(the Kd for RARs is 1000 nM (11)). This raises the question as
to why, unlike 9cRA, LG268 is unable to bind to and activate
RARs. Fig. 3 shows a comparison of the hRAR and hRXR
ligand binding pockets. Superposition of the RXR and RAR
structures on helices H5 and H11 provides the most instructive
comparison of the two structures. It is clear that the paths of
helix H3, the -sheet, as well as helices H6 and H7 adopt
significantly different conformations relative to helices H5 and
H11 and the rest of the structure (Fig. 3, a and b). These
differences in secondary structure positioning, along with dif-
ferent side chain identities, result in a differently shaped li-
gand binding pocket (Fig. 3, c and d). In particular the side
chains of residues Leu-268, Met-272, Phe-288, Phe-304, Gly-
393, Arg-396, and Ala-397 in hRAR combine to create a rela-
tively linear cavity suited to accommodate the extended con-
formation of all-trans retinoic acid (atRA). The corresponding
residues in hRXR (Asn-377, Ile-381, Leu-397, Val-413, Cys-
503, His-506, and Leu-507) create a more globular cavity suited
to accommodate a shorter “bent” ligand such as LG268 or 9cRA.
Interestingly the side chain of Arg-387 is able to adjust its
position so as to reach 2 Å further into the ligand binding
cavity to form a salt bridge with the carboxylate of LG268.
These observations support the previous suggestion that it is
the ability of 9cRA to flex that allows it to bind to both RARs
and RXRs (35). The fact that LG268 is fixed in a bent confor-
mation by the tetrahedral geometry around the cyclopropyl
group means that it is unable to adopt the linear conformation
needed to bind hRAR and would therefore clash with the side
chains of residues Phe-288, Phe-304, and Met-272. Similarly,
atRA is fixed in a linear conformation and could not adapt to
the shorter ligand binding cavity of RXR.
Homodimerization—In the structure of the hRXR bound to
LG268, the receptor LBD forms a homodimer. The homodimer-
ization interface is essentially identical to that observed in the
apo-hRXR dimer interface (27, 33). In previous crystals of
liganded RXRs, the LBD was found to be either monomeric or
bound as a heterodimer to a partner receptor (36–38). Because
the apo-hRXR was found to be a dimer or tetramer, it has
been suggested that ligand binding favors dissociation of RXR
FIG. 2. Contacts to LG268 and comparison with hRXR:9cRA.
a, the ligand binding pocket of hRXR:LG268. The 2Fo  Fc electron
density for the ligand is shown in blue (contoured at  1). The electron
density shown is prior to refinement but after averaging according to
the 4-fold noncrystallographic symmetry and allows unambiguous plac-
ing of the ligand. Side chains that contact the ligand are shown in green
(within 4.5 Å), and a water molecule is shown as a blue sphere. b,
schematic representation of the contacts between the protein and the
LG268 ligand. c, superposition of the ligand binding cavities of hRXR:
LG268 (green) and hRXR:9cRA (red) (38) (Protein Data Bank code
1fby). Side chains that reorientate to accommodate the different ligands
are labeled.
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oligomers and the formation of monomers or heterodimers (38,
39). However, a comparison with the hRXR:9cRA structure
suggests no obvious reason why it should be monomeric,
whereas hRXR:LG268 (and indeed the apo-hRXR) is a ho-
modimer. It is therefore unclear how ligand binding might
favor dissociation of the homodimer, and it seems likely that
the hRXR:9cRA crystal lattice favors the monomer.
A novel Position for Helix H12—As mentioned above, helix
H12 adopts an unexpected orientation in the structure of
hRXR bound to LG268. It is positioned such that it is folded
under the ligand-binding domain and makes no contacts to the
main body of the protein (Fig. 1b). Residues beyond Leu-522
are rather disordered. Because LG268 is a strongly activating
ligand, we expected helix H12 to adopt the canonical active
position. Accordingly, we examined the packing in the crystal
lattice to determine whether it was compatible with the ex-
pected position of helix H12. It appears that for two adjacent
proteins, one but not both could have helix H12 in the canonical
position. Thus the crystal lattice precludes half of proteins from
adopting the canonical position for helix H12. This raises the
question: was helix H12 displaced from the expected position
during crystallization or did the crystals select molecules in
FIG. 3. Comparison with hRAR:atRA. a, differences between hRXR:LG268 (green) and hRAR:atRA (blue) (47) (Protein Data Bank code
2lbd) ligand binding pockets. The structures were superimposed using helices H5 and H11 (gray). Helices H3 and H7 and the -sheet adopt largely
different conformations in order to bind atRA. b, the critical amino acid residues that discriminate between RXR- and RAR-specific agonists. c–d,
the shapes of the RXR (green) and RAR (blue) ligand-binding cavities. The cavity within RXR has a more globular shape in comparison with the
more elongated RAR cavity.
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which the helix was already elsewhere? In either situation it
suggests that helix H12 is rather weakly recruited to the active
position on binding ligand.
We and others (18–20, 40) have previously proposed that the
repositioning of helix H12 is critical to the displacement of
co-repressor proteins and the recruitment of co-activators. We
have used mammalian two-hybrid assays to explore the role of
LG268 in regulating co-factor interactions. These experiments
show that, unlike other receptors such as TR and RAR, VP-
RXR is efficiently recruited to the co-repressor hybrid Gal-
SMRT even in the presence of ligand (Fig. 4). However, the
addition of increasing amounts of the co-activator ACTR (fused
to the SV40 nuclear localization signal) is able to compete for
the VP-RXR such that interaction with Gal-SMRT is abolished.
These results show that ligand alone is unable to reposition
helix H12 and displace co-repressor. However in the presence
of ligand, the co-activator is able to displace the co-repressor,
resulting in an active complex. We propose that while RXR
ligands are absolutely required for the recruitment of co-acti-
vators, they are insufficient to displace co-repressors unless
co-activator is also present.
DISCUSSION
The application of synthetic chemistry techniques to the
development of novel nuclear receptor ligands has proven ex-
traordinarily powerful. It has been possible to derive receptor
and isoform specific ligands, which do not occur in nature, as
well as compounds with activities ranging from superactive
agonists through to powerful antagonists. A remarkable fea-
ture of these synthetic ligands is that it is possible to generate
a wide range of activities that depend upon their detailed
chemistry rather than just their dissociation constants. This
suggests that the activity of the receptor can be fine-tuned
across a broad range of activity.
The retinoid-X receptor is an important therapeutic target
for synthetic agonists because it is involved in a wide range of
biological processes. Potential applications include the treat-
ment of cancer and diabetes and the lowering of circulatory
cholesterol.
To understand the structural and chemical bases for the
specificity, 3–4-fold higher affinity, and10-fold greater trans-
activation activity of LG268 compared with 9cRA, we crystal-
lized the ligand with the human RXR ligand-binding domain.
The structure reveals that several factors are likely to contrib-
ute to the greater affinity of LG268 for RXR. First, the syn-
thetic ligand has a 13% larger volume than 9cRA (355 versus
315 Å3) and thus occupies a greater fraction of the ligand-
binding cavity (63% versus 57%) and has a correspondingly
greater surface area of contact with the protein. Second, com-
pared with 9cRA, LG268 is comparatively rigid such that the
only free movement is the rotation of the naphthalene and
piperidine rings. LG268 binding is therefore likely to be en-
tropically favored compared with 9cRA. Indeed the geometry
and volume of the cyclopropyl group would appear to be critical
for the high binding affinity. The angle between the piperidine
and naphthalene groups is fixed at 109°. If the cyclopropyl
group is replaced with a smaller trigonal carbonyl or alkene
group, the affinity is reduced then by 10-fold (11).
Interestingly the increased transactivation activity of LG268
compared with 9cRA is proportionally greater than the in-
creased binding affinity; which suggests that there is a second-
ary mechanism for this enhancement. A comparison of the
FIG. 5. Potential contacts between LG268 and helix H12. Su-
perimposition of hRXR:LG268 (green) and hRXR:9cRA:CoA (yellow)
(37) (Protein Data Bank code 1fm6). Note that 9cRA makes no contact
with residues in helix H12. LG268, however, is able to contact a leucine
side chain in helix H12 via the methyl substituent on the unsaturated
ring of the naphthalene. It is likely that in the LG268 complex this
contact stabilizes helix H12 and facilitates co-activator binding com-
pared with 9cRA. This may explain the significantly higher transcrip-
tional activation by LG268 compared with 9cRA (some helices were
removed for clarity).
FIG. 4. RXR ligands are inefficient at displacing co-repressor in the absence of co-activator. Mammalian two-hybrid interaction assays
indicate that unliganded receptors (TR, RAR, and RXR) all interact with the co-repressor protein SMRT. The addition of ligand results in
dissociation of TR and RAR but not RXR (left panel). Increasing amounts of the co-activator ACTR, however, is able to displace co-repressor from
RXR in the presence of ligand (middle panel). The right-hand panel shows the control experiment that ligand promotes co-activator interaction in
the absence of co-repressor. Thus, ligand is absolutely required for the recruitment of co-activators but is insufficient to displace co-repressors from
RXR.
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structure with that of hRXR:9cRA:co-activator (37) (Fig. 5)
indicates that unlike 9cRA, LG268 can make a direct contact
with a leucine in helix H12. This contact is mediated by the
methyl substituent on the unsaturated ring of the naphtha-
lene. Thus LG268, but not 9cRA, is able to directly stabilize
helix H12 and its interaction with co-activator. When a more
bulky group occupies this position, the ligand acts as an antag-
onist, as demonstrated by the compound LG100754 (41, 42).
The C-terminal helix H12 of nuclear receptors plays a critical
role in regulating the receptor. Receptors that lack helix H12
are unable to release co-repressors even in the presence of
agonists and are equally unable to recruit co-activators (43–
45). These observations fit well with our understanding of
nuclear receptor structures. In its active conformation, helix
H12 makes direct contacts with the coactivator helix and, in
many receptors, with the ligand itself. Mutations that disturb
that active position of helix H12 result in a loss of transactiva-
tion activity because of the inability to recruit coactivator (46).
In the absence of ligand it has been proposed that helix H12 is
displaced by co-repressor and so must adopt an alternate posi-
tion or positions (18–20, 40). In a variety of unliganded antag-
onist and partial agonist bound structures, helix H12 has been
seen to occupy a range of alternate positions. These observa-
tions suggest that helix H12 may exist in an equilibrium be-
tween various conformations. The position of the helix H12
equilibrium is likely to depend upon the nature of the ligand
bound to the receptor.
We have shown that in the structure of hRXR bound to the
synthetic agonist LG268, helix H12 does not adopt the active
conformation. This may be a consequence of the packing in the
crystal lattice trapping a particular position of helix H12. How-
ever, two lines of evidence suggest that the helix H12 position
seen in the crystal may be indicative of the behavior of helix
H12 in vivo. First, helix H12 of RXR is equally sensitive to
proteolytic cleavage both in the presence and absence of ligand
(44). This contrasts with other receptors, such as TR, and
suggests that the accessibility of helix H12 in RXR is not
influenced greatly by ligand and therefore that ligand may only
weakly recruit helix H12 to the active conformation. Second,
mammalian two-hybrid experiments suggest that efficient dis-
placement of co-repressor by helix H12 requires the presence of
both ligand and co-activator. We conclude from these observa-
tions that helix H12 in RXR is likely to be more mobile and less
influenced by ligand alone than in certain other nuclear recep-
tors. Indeed, the differences in the mobility of helix H12 among
different receptors and receptor-ligand complexes are likely to
underlie the widely diverse behavior of different receptors and
ligands.
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